<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOZOL- indapamide tablet, film coated </strong><br>Aventis Pharmaceuticals Inc.<br></p></div>
<h1>Lozol<span class="Sup">®</span><br>(indapamide)<br>1.25 mg tablets</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Lozol<span class="Sup">®</span> (indapamide) is an oral antihypertensive/diuretic. Its molecule contains both a polar sulfamoyl chlorobenzamide moiety and a lipid-soluble methylindoline moiety. It differs chemically from the thiazides in that it does not possess the thiazide ring system and contains only one sulfonamide group. The chemical name of Lozol is 1-(4-chloro-3-sulfamoylbenzamido)-2-methylindoline, and its molecular weight is 365.84. The compound is a weak acid, pK<span class="Sub">a</span>=8.8, and is soluble in aqueous solutions of strong bases. It is a white to yellow-white crystalline (tetragonal) powder.</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=289796B5-F95C-4C40-BAD7-D6359E0F7840&amp;name=lozol-image01.jpg"></div>
<p>The tablets also contain microcrystalline cellulose, coloring agent, corn starch, pregelatinized starch, hypromellose, lactose, magnesium stearate, polyethylene glycol, and talc.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Indapamide is the first of a new class of antihypertensive/diuretics, the indolines. The oral administration of 2.5 mg (two 1.25 mg tablets) of indapamide to male subjects produced peak concentrations of approximately 115 ng/mL of the drug in blood within two hours. The oral administration of 5 mg (two 2.5 mg tablets) of indapamide to healthy male subjects produced peak concentrations of approximately 260 ng/mL of the drug in the blood within two hours. A minimum of 70% of a single oral dose is eliminated by the kidneys and an additional 23% by the gastrointestinal tract, probably including the biliary route. The half-life of Lozol in whole blood is approximately 14 hours.</p>
<p>Lozol is preferentially and reversibly taken up by the erythrocytes in the peripheral blood. The whole blood/plasma ratio is approximately 6:1 at the time of peak concentration and decreases to 3.5:1 at eight hours. From 71 to 79% of the Lozol in plasma is reversibly bound to plasma proteins.</p>
<p>Lozol is an extensively metabolized drug, with only about 7% of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration. The urinary elimination of <span class="Sup">14</span>C-labeled indapamide and metabolites is biphasic with a terminal half-life of excretion of total radioactivity of 26 hours.</p>
<p>In a parallel design double-blind, placebo controlled trial in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, daily doses of indapamide between 1.25 mg and 10.0 mg produced dose-related antihypertensive effects. Doses of 5.0 and 10.0 mg were not distinguishable from each other although each was differentiated from placebo and 1.25 mg indapamide. At daily doses of 1.25 mg, 5.0 mg and 10.0 mg, a mean decrease of serum potassium of 0.28, 0.61 and 0.76 mEq/L, respectively, was observed and <span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">uric acid increased</span> by about 0.69 mg/100 mL.</p>
<p>In other parallel design, dose-ranging clinical trials in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, daily doses of indapamide between 0.5 and 5.0 mg produced dose-related effects. Generally, doses of 2.5 and 5.0 mg were not distinguishable from each other although each was differentiated from placebo and from 0.5 or 1.0 mg indapamide. At daily doses of 2.5 and 5.0 mg a mean decrease of serum potassium of 0.5 and 0.6 mEq/Liter, respectively, was observed and <span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">uric acid increased</span> by about 1.0 mg/100 mL.</p>
<p>At these doses, the effects of indapamide on blood pressure and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> are approximately equal to those obtained with conventional doses of other antihypertensive/diuretics.</p>
<p>In hypertensive patients, daily doses of 1.25, 2.5 and 5.0 mg of indapamide have no appreciable cardiac inotropic or chronotropic effect. The drug decreases peripheral resistance, with little or no effect on <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, rate or rhythm. Chronic administration of indapamide to hypertensive patients has little or no effect on glomerular filtration rate or renal plasma flow.</p>
<p>Lozol had an antihypertensive effect in patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, although in general, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuretic effects</span> declined as renal function decreased.</p>
<p>In a small number of controlled studies, Indapamide taken with other antihypertensive drugs such as hydralazine, propranolol, guanethidine and methyldopa, appeared to have the additive effect typical of thiazide-type diuretics.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">Lozol is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, alone or in combination with other antihypertensive drugs.</p>
<p>Lozol is also indicated for the treatment of salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> associated with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span> below).</p>
<p>Diuretics do not prevent development of <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span>, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia.</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Indapamide is indicated in pregnancy when <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> is due to pathologic causes, just as it is in the absence of pregnancy (however, see <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span> below). <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span> in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, including <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span> in the majority of pregnant women. If this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> produces <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, increased recumbency will often provide relief. In rare instances, this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may cause extreme <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>.</p>
<p>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to indapamide or to other sulfonamide-derived drugs.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Severe cases of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, accompanied by <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> have been reported with recommended doses of indapamide. This occurred primarily in elderly females. (See <span class="Bold"><a href="#precautions_geriatric">PRECAUTIONS, Geriatric Use</a></span>.) This appears to be dose related. Also, a large case-controlled pharmacoepidemiology study indicates that there is an increased risk of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> with indapamide 2.5 mg and 5 mg doses. <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> considered possibly clinically significant (&lt; 125 mEq/L) has not been observed in clinical trials with the 1.25 mg dosage (see <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>). Thus, patients should be started at the 1.25 mg dose and maintained at the lowest possible dose. (See <span class="Bold"><a href="#dosage_administration">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> occurs commonly with diuretics (see <span class="Bold"><a href="#adverse_reactions">ADVERSE REACTIONS</a></span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>), and electrolyte monitoring is essential, particularly in patients who would be at increased risk from <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, such as those with <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> or who are receiving concomitant cardiac glycosides.</p>
<p>In general, diuretics should not be given concomitantly with lithium because they reduce its renal clearance and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Read prescribing information for lithium preparations before use of such concomitant therapy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>, and Other Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Imbalances</span></h3>
<p class="First">Periodic determinations of serum electrolytes should be performed at appropriate intervals. In addition, patients should be observed for clinical signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, such as <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, or <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Warning signs include <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbance</span>. Electrolyte determinations are particularly important in patients who are <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving parenteral fluids, in patients subject to <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> (including those with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, kidney disease, and cirrhosis), and in patients on a salt-restricted diet.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> secondary to <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> and natriuresis is increased when larger doses are used, when the <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> is brisk, when severe cirrhosis is present and during concomitant use of corticosteroids or ACTH. Interference with adequate oral intake of electrolytes will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> can sensitize or exaggerate the response of the heart to the toxic effects of digitalis, such as increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>.</p>
<p>Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients; the appropriate treatment is restriction of water rather than administration of salt, except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life threatening. However, in actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the treatment of choice. Any chloride deficit that may occur during treatment is generally mild and usually does not require specific treatment except in extraordinary circumstances as in liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Thiazide-like diuretics have been shown to increase the urinary excretion of magnesium; this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> and <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span></h3>
<p class="First">Serum concentrations of <span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">uric acid increased</span> by an average of 0.69 mg/100 mL in patients treated with indapamide 1.25 mg, and by an average of 1.0 mg/100 mL in patients treated with indapamide 2.5 mg and 5.0 mg, and frank <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving indapamide (see <span class="Bold"><a href="#adverse_reactions">ADVERSE REACTIONS</a></span> below). Serum concentrations of uric acid should, therefore, be monitored periodically during treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">Indapamide, like the thiazides, should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, as reduced plasma volume may exacerbate or precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. If progressive <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is observed in a patient receiving indapamide, withholding or discontinuing diuretic therapy should be considered. Renal function tests should be performed periodically during treatment with indapamide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.4"></a><p></p>
<h3>Impaired Hepatic Function</h3>
<p class="First">Indapamide, like the thiazides, should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.5"></a><p></p>
<h3>Glucose Tolerance</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">Latent diabetes</span> may become manifest and insulin requirements in diabetic patients may be altered during thiazide administration. A mean increase in glucose of 6.47 mg/dL was observed in patients treated with indapamide 1.25 mg, which was not considered clinically significant in these trials. Serum concentrations of glucose should be monitored routinely during treatment with Lozol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.6"></a><p></p>
<h3>Calcium Excretion</h3>
<p class="First">Calcium excretion is decreased by diuretics pharmacologically related to indapamide. After six to eight weeks of indapamide 1.25 mg treatment and in long-term studies of hypertensive patients with higher doses of indapamide, however, serum concentrations of calcium increased only slightly with indapamide. Prolonged treatment with drugs pharmacologically related to indapamide may in rare instances be associated with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> secondary to physiologic changes in the parathyroid gland; however, the common complications of <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>, such as renal lithiasis, bone resorption, and <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, have not been seen. Treatment should be discontinued before tests for parathyroid function are performed. Like the thiazides, indapamide may decrease serum PBI levels without signs of thyroid disturbance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.7"></a><p></p>
<h3>Interaction With <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></h3>
<p class="First">Thiazides have exacerbated or activated <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> and this possibility should be considered with indapamide as well.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<h3>Other Antihypertensives</h3>
<p class="First">Lozol may add to or potentiate the action of other antihypertensive drugs. In limited controlled trials that compared the effect of indapamide combined with other antihypertensive drugs with the effect of the other drugs administered alone, there was no notable change in the nature or frequency of adverse reactions associated with the combined therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.2"></a><p></p>
<h3>Lithium</h3>
<p class="First">See <span class="Bold"><a href="#warnings">WARNINGS</a></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.3"></a><p></p>
<h3>Post-Sympathectomy Patient</h3>
<p class="First">The antihypertensive effect of the drug may be enhanced in the post-sympathectomized patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.4"></a><p></p>
<h3>Norepinephrine</h3>
<p class="First">Indapamide, like the thiazides, may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Both mouse and rat lifetime carcinogenicity studies were conducted. There was no significant difference in the incidence of tumors between the indapamide-treated animals and the control groups.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.4.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<p class="First"><span class="Italics">Pregnancy Category B.</span></p>
<p>Reproduction studies have been performed in rats, mice and rabbits at doses up to 6,250 times the therapeutic human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Lozol® (indapamide). Postnatal development in rats and mice was unaffected by pretreatment of parent animals during gestation. There are, however, no adequate and well-controlled studies in pregnant women. Moreover, diuretics are known to cross the placental barrier and appear in cord blood. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. There may be hazards associated with this use such as fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in the adult.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because most drugs are excreted in human milk, if use of this drug is deemed essential, the patient should stop nursing.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of indapamide in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="precautions_geriatric"></a><a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of indapamide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Severe cases of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, accompanied by <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> have been reported with recommended doses of indapamide in elderly females (see <span class="Bold"><a href="#warnings">WARNINGS</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse_reactions"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Most adverse effects have been mild and transient.</p>
<p>The Clinical Adverse Reactions listed in Table 1 represent data from Phase II/III placebo-controlled studies (306 patients given indapamide 1.25 mg). The Clinical Adverse Reactions listed in Table 2 represent data from Phase II placebo-controlled studies and long-term controlled clinical trials (426 patients given Lozol 2.5 mg or 5.0 mg). The reactions are arranged into two groups: 1) a cumulative incidence equal to or greater than 5%; 2) a cumulative incidence less than 5%. Reactions are counted regardless of relation to drug.</p>
<table width="60%">
<caption><span>TABLE 1: Adverse Reactions from Studies of 1.25 mg</span></caption>
<col align="left" width="30%">
<col align="left" width="30%">
<thead><tr class="First Last">
<th align="left">Incidence ≥ 5%</th>
<th align="left">Incidence &lt; 5%<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>OTHER</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">BODY AS A WHOLE</td>
<td class="Lrule" align="left"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu Syndrome</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
</tr>
<tr>
<td align="left">GASTROINTESTINAL SYSTEM</td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
</tr>
<tr>
<td align="left">METABOLIC SYSTEM</td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></td>
</tr>
<tr>
<td align="left">CENTRAL NERVOUS SYSTEM</td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span></td>
</tr>
<tr>
<td align="left">RESPIRATORY SYSTEM</td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
</tr>
<tr class="Last">
<td align="left">SPECIAL SENSES</td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></td>
</tr>
</tbody>
</table>
<p>All other clinical adverse reactions occurred at an incidence of &lt;1%.</p>
<p>Approximately 4% of patients given indapamide 1.25 mg compared to 5% of the patients given placebo discontinued treatment in the trials of up to eight weeks because of adverse reactions.</p>
<p>In controlled clinical trials of six to eight weeks in duration, 20% of patients receiving indapamide 1.25 mg, 61% of patients receiving indapamide 5.0 mg, and 80% of patients receiving indapamide 10.0 mg had at least one potassium value below 3.4 mEq/L. In the indapamide 1.25 mg group, about 40% of those patients who reported <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> as a laboratory adverse event returned to normal serum potassium values without intervention. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> with concomitant clinical signs or symptoms occurred in 2% of patients receiving indapamide 1.25 mg.</p>
<table width="75%">
<caption><span>TABLE 2: Adverse Reactions from Studies of 2.5 mg and 5.0 mg</span></caption>
<col align="left" width="40%">
<col align="left" width="35%">
<thead><tr class="First Last">
<th align="left">Incidence ≥ 5%</th>
<th align="left">Incidence &lt; 5%</th>
</tr></thead>
<tbody>
<tr class="First"><td align="left" colspan="2">CENTRAL NERVOUS SYSTEM/NEUROMUSCULAR</td></tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, loss</td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
</tr>
<tr>
<td align="left">  of energy, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, or <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span> or</td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
</tr>
<tr>
<td align="left">  spasm, or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> of the extremities</td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>,</td>
<td class="Lrule" align="left"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span></td>
<td class="Lrule" align="left"></td>
</tr>
<tr>
<td align="left">GASTROINTESTINAL SYSTEM</td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">Gastric irritation</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
</tr>
<tr>
<td align="left">CARDIOVASCULAR SYSTEM</td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">Premature ventricular contractions</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left">Irregular heart beat</td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
</tr>
<tr>
<td align="left">GENITOURINARY SYSTEM</td>
<td class="Lrule" align="left">Frequency of urination</td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">Nocturia</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Polyuria</span></td>
</tr>
<tr>
<td align="left">DERMATOLOGIC/ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">Vasculitis</span></td>
</tr>
<tr>
<td align="left">OTHER</td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span> or reduced libido</td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Rhinorrhea</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">Hypochloremia</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left">Increase in serum urea nitrogen</td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left">  (BUN) or creatinine</td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">Glycosuria</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span></td>
</tr>
<tr>
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
</tr>
<tr class="Last">
<td align="left"></td>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Tingling</span> of extremities</td>
</tr>
</tbody>
</table>
<p>Because most of these data are from long-term studies (up to 40 weeks of treatment), it is probable that many of the adverse experiences reported are due to causes other than the drug. Approximately 10% of patients given indapamide discontinued treatment in long-term trials because of reactions either related or unrelated to the drug.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> with concomitant clinical signs or symptoms occurred in 3% of patients receiving indapamide 2.5 mg q.d. and 7% of patients receiving indapamide 5 mg q.d. In long-term controlled clinical trials comparing the hypokalemic effects of daily doses of indapamide and hydrochlorothiazide, however, 47% of patients receiving indapamide 2.5 mg, 72% of patients receiving indapamide 5 mg, and 44% of patients receiving hydrochlorothiazide 50 mg had at least one potassium value (out of a total of 11 taken during the study) below 3.5 mEq/L. In the indapamide 2.5 mg group, over 50% of those patients returned to normal serum potassium values without intervention.</p>
<p>In clinical trials of six to eight weeks, the mean changes in selected values were as shown in the tables below.</p>
<table width="80%">
<col align="left" width="15%">
<col align="center" width="10%">
<col align="center" width="10%">
<col align="center" width="10%">
<col align="center" width="20%">
<col align="center" width="15%">
<thead>
<tr class="First"><th align="center" colspan="6">Mean Changes from Baseline after 8 Weeks of Treatment – 1.25 mg</th></tr>
<tr class="Last">
<th class="Toprule" align="left"></th>
<th class="Lrule Toprule" align="center" colspan="3">Serum Electrolytes (mEq/L)<br>Potassium Sodium Chloride</th>
<th class="Lrule Toprule" align="center">Serum Uric Acid<br>(mg/dL)</th>
<th class="Lrule Toprule" align="center">BUN<br>(mg/dL)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">Indapamide<br>  1.25 mg<br>  (n=255–257)</td>
<td class="Lrule" align="center" valign="middle">– 0.28</td>
<td align="center" valign="middle">– 0.63</td>
<td align="center" valign="middle">– 2.60</td>
<td class="Lrule" align="center" valign="middle">0.69</td>
<td class="Lrule" align="center" valign="middle">1.46</td>
</tr>
<tr class="Last">
<td class="Toprule" align="left">Placebo<br>  (n=263–266)</td>
<td class="Lrule Toprule" align="center" valign="bottom">0.00</td>
<td class="Toprule" align="center" valign="bottom">– 0.11</td>
<td class="Toprule" align="center" valign="bottom">– 0.21</td>
<td class="Lrule Toprule" align="center" valign="bottom">0.06</td>
<td class="Lrule Toprule" align="center" valign="bottom">0.06</td>
</tr>
</tbody>
</table>
<p>No patients receiving indapamide 1.25 mg experienced <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> considered possibly clinically significant (&lt;125 mEq/L).</p>
<p>Indapamide had no adverse effects on lipids.</p>
<table width="80%">
<col align="left" width="15%">
<col align="center" width="10%">
<col align="center" width="10%">
<col align="center" width="10%">
<col align="center" width="20%">
<col align="center" width="15%">
<thead>
<tr class="First"><th align="center" colspan="6">Mean Changes from Baseline after 40 Weeks of Treatment – 2.5 mg and 5.0 mg</th></tr>
<tr class="Last">
<th class="Toprule" align="left"></th>
<th class="Lrule Toprule" align="center" colspan="3">Serum Electrolytes (mEq/L)<br>Potassium Sodium Chloride</th>
<th class="Lrule Toprule" align="center">Serum Uric Acid<br>(mg/dL)</th>
<th class="Lrule Toprule" align="center">BUN<br>(mg/dL)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left">Indapamide<br>  2.5 mg (n=76)</td>
<td class="Lrule" align="center" valign="top">– 0.4</td>
<td align="center" valign="top">– 0.6</td>
<td align="center" valign="top">– 3.6</td>
<td class="Lrule" align="center" valign="top">0.7</td>
<td class="Lrule" align="center" valign="top">– 0.1</td>
</tr>
<tr class="Last">
<td align="left">Indapamide<br>  5.0 mg (n=81)</td>
<td class="Lrule" align="center" valign="top">– 0.6</td>
<td align="center" valign="top">– 0.7</td>
<td align="center" valign="top">– 5.1</td>
<td class="Lrule" align="center" valign="top">1.1</td>
<td class="Lrule" align="center" valign="top">1.4</td>
</tr>
</tbody>
</table>
<p>The following reactions have been reported with clinical usage of Lozol: <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>. These reactions were reversible with discontinuance of the drug.</p>
<p>Also reported are <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruptions</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>. Other adverse reactions reported with antihypertensive/diuretics are necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Symptoms of overdosage include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> and disturbances of electrolyte balance. In severe instances, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and depressed respiration may be observed. If this occurs, support of respiration and cardiac circulation should be instituted. There is no specific antidote. An evacuation of the stomach is recommended by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> and gastric lavage after which the electrolyte and fluid balance should be evaluated carefully.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage_administration"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">The adult starting indapamide dose for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is 1.25 mg as a single daily dose taken in the morning. If the response to 1.25 mg is not satisfactory after four weeks, the daily dose may be increased to 2.5 mg taken once daily. If the response to 2.5 mg is not satisfactory after four weeks, the daily dose may be increased to 5.0 mg taken once daily, but adding another antihypertensive should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></h2>
<p class="First">The adult starting indapamide dose for <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> is 2.5 mg as a single daily dose taken in the morning. If the response to 2.5 mg is not satisfactory after one week, the daily dose may be increased to 5.0 mg taken once daily.</p>
<p>If the antihypertensive response to indapamide is insufficient, Lozol may be combined with other antihypertensive drugs, with careful monitoring of blood pressure. It is recommended that the usual dose of other agents be reduced by 50% during initial combination therapy. As the blood pressure response becomes evident, further dosage adjustments may be necessary.</p>
<p>In general, doses of 5.0 mg and larger have not appeared to provide additional effects on blood pressure or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, but are associated with a greater degree of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. There is minimal clinical trial experience in patients with doses greater than 5.0 mg once a day.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<table width="75%">
<col align="center" width="12%">
<col align="center" width="15%">
<col align="center" width="12%">
<col align="center" width="12%">
<col align="center" width="12%">
<col align="center" width="12%">
<thead><tr class="First Last">
<th align="center">Strength</th>
<th align="center">Size</th>
<th align="center">NDC 0075-</th>
<th align="center">Color</th>
<th align="center">Shape</th>
<th align="center">Markings</th>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">1.25 mg</td>
<td class="Lrule" align="center">Bottles of 100<br>Bottles of 1000</td>
<td class="Lrule" align="center">0700-00<br>0700-99</td>
<td class="Lrule" align="center">Orange,<br>film-coated</td>
<td class="Lrule" align="center">Octagon<br>Shaped</td>
<td class="Lrule" align="center">R<br>and<br>7</td>
</tr></tbody>
</table>
<p class="First">U.S. Pat. No. Des. 300,673.</p>
<p><span class="Bold">Keep out of the reach of children.</span></p>
<p>Keep tightly closed. Store at Controlled Room Temperature 20 to 25°C (68 to 77°F) [see USP]. Avoid excessive heat. This product should be dispensed in a container with a child resistant cap.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Rev. July 2005</p>
<p>Aventis Pharmaceuticals Inc.<br>Bridgewater, NJ 08807 USA<br>©2005 Aventis Pharmaceuticals Inc.</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOZOL 		
					</strong><br><span class="contentTableReg">indapamide tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-0700</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>indapamide</strong> (indapamide) </td>
<td class="formItem"></td>
<td class="formItem">1.25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>coloring agent</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>corn starch</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>pregelatinized starch</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromellose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange (orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OCTAGON (8 sided) (OCTAGON (8 sided)) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">R;7</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">true</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-0700-00</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0075-0700-99</td>
<td class="formItem">1000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Aventis Pharmaceuticals Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>06B7A77C-9BFC-29BB-B8CC-1A67869BCF6D</div>
<div>Set id: 289796B5-F95C-4C40-BAD7-D6359E0F7840</div>
<div>Version: 3</div>
<div>Effective Time: 20080904</div>
</div>
</div> <div class="DistributorName">Aventis Pharmaceuticals Inc.</div></p>
</body></html>
